← Back to Search
Immunotherapy Of Malignant Peritoneal Mesothelioma And Pseudomyxoma Peritonei
Irina Zh. Zhubina, I. Chikileva, M. V. Kiselevskiy
Published 2019 · Medicine
Download PDFAnalyze on Scholarcy
Immunotherapy of malignant peritoneal mesothelioma and pseudomixoma peritonei is a promising method and is actively developed to treat patients with these malignancies. The approach includes methods of adoptive cellular immunotherapy with local infusions of autologic activated or genetically modified lymphocytes and target drugs based on monoclonal antibodies, including immune checkpoint inhibitors.
This paper references
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma
J. Lai (2016)
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
R. Hassan (2007)
Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
N. Hacohen (2013)
Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial
P. Queirolo (1999)
What's the place of immunotherapy in malignant mesothelioma treatments?
M. Grégoire (2010)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
S. H. Goey (1995)
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
R. Hassan (2014)
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
R. Hassan (2013)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
R. Kreitman (2009)
Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
R. Hassan (2002)
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.
W. van den Ancker (2010)
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.
M. Rajasagi (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
E. Tran (2014)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Q. Li (2004)
Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
E. Servais (2012)
A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy.
P. Baas (2011)
T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product
Jianping Huang (2004)
Malignant mesothelioma 2008
M. Zervos (2008)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
P. Adusumilli (2014)
Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells
R. May (2007)
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
R. Hassan (2010)
Dendritic cell-based immunotherapy in mesothelioma.
R. Cornelissen (2012)
OA13.06 Autologous Dendritic Cells Loaded with Allogeneic Tumor Cell Lysate (Pheralys®) in Patients with Mesothelioma: Final Results of a Phase I Study
J. Aerts (2017)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
M. Mayor (2016)
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
J. Hegmans (2010)
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
J. Stevenson (2013)
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
R. Junghans (2017)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Rachel S. Zolot (2013)
Review on clinical trials of targeted treatments in malignant mesothelioma
J. N. Jakobsen (2011)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
Discovery of mesothelin and exploiting it as a target for immunotherapy.
I. Pastan (2014)
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
A. Gauvrit (2008)
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
R. Hassan (2010)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
L. Wang (2013)
Phase I/II study of tumor-infiltrating lymphocyte (TIL) infusion and low-dose interleukin-2 (IL-2) in patients with advanced malignant pleural mesothelioma (MPM).
M. Doherty (2015)